铜绿假单胞菌临床分离株的流行病学调查及中药活性成分抑菌效果的初步研究_第1页
铜绿假单胞菌临床分离株的流行病学调查及中药活性成分抑菌效果的初步研究_第2页
铜绿假单胞菌临床分离株的流行病学调查及中药活性成分抑菌效果的初步研究_第3页
铜绿假单胞菌临床分离株的流行病学调查及中药活性成分抑菌效果的初步研究_第4页
铜绿假单胞菌临床分离株的流行病学调查及中药活性成分抑菌效果的初步研究_第5页
已阅读5页,还剩21页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

铜绿假单胞菌临床分离株的流行病学调查及中药活性成分抑菌效果的初步研究摘要目的:初步分析铜绿假单胞菌临床分离株耐药性及流行病学特点并进行中药活性成分抑菌效果的初步研究,为防治感染和临床用药提供参考。方法:采用微量肉汤稀释法检测临床常用抗生素及中药活性成分抑制铜绿假单胞菌的最低抑菌浓度(MIC)值,棋盘稀释法测定抗生素与中药活性成分联用的抑菌效果,结晶紫法检测中药活性成分抑制铜绿假单胞菌生物膜形成实验,迁移实验检测中药活性成分抑制铜绿假单胞菌表面运动性。结果:本研究收集的质控菌株ATCC27853及39株临床分离的铜绿假单胞菌对碳青霉烯类和喹诺酮类药物耐药性较高,对氨基糖苷类和青霉素类药物敏感性较高,中药活性成分联用效果不太理想。结论:临床用药可使用青霉素类和氨基糖苷类药物,中药活性成分的临床应用还需要进一步的探究。关键词:铜绿假单胞菌;最低抑菌浓度;流行病学;中药活性成分EpidemiologicalinvestigationofclinicalisolatesofPseudomonasaerμginosaandpreliminarystudyontheantibacterialeffectofactiveingredientsoftraditionalChinesemedicineAbstractObjective:ToinvestigatethedrμgresistanceandepidemiologicalcharacteristicsofclinicalisolatesofPseudomonasaerμginosa,andtoconductapreliminarystudyontheantibacterialeffectsofactiveingredientsoftraditionalChinesemedicine,inordertoprovidereferenceforthepreventionandtreatmentofinfectionsandclinicalmedication.Method:Theminimuminhibitoryconcentration(MIC)valuesofcommonlyusedantibioticsandactiveingredientsoftraditionalChinesemedicineagainstPseudomonasaerμginosaweremeasuredusingamicrobrothdilutionmethod.TheantibacterialeffectofthecombinationofantibioticsandactiveingredientsoftraditionalChinesemedicinewasmeasuredusingachessboarddilutionmethod.ThecrystalvioletmethodwasusedtodetecttheinhibitoryeffectofactiveingredientsoftraditionalChinesemedicineonthebiofilmformationofPseudomonasaerμginosa.ThemigrationexperimentwasusedtodetecttheinhibitoryeffectofactiveingredientsoftraditionalChinesemedicineonthesurfacemotilityofPseudomonasaerμginosa.Result:ThequalitycontrolstrainATCC27853and39clinicalisolatesofPseudomonasaeruginosacollectedinthisstudyhavehighresistancetocarbapenemsandquinolones,andhighsensitivitytoaminoglycosidesandpenicillindrugs.ThecombineduseofactiveingredientsfromtraditionalChinesemedicineisnotideal.Conclusion:Penicillinsandaminoglycosidescanbeusedinclinicalmedication,andfurtherexplorationisneededfortheclinicalapplicationofactiveingredientsintraditionalChinesemedicine.Keywords:Pseudomonasaerμginosa;Minimuminhibitoryconcentration;Epidemiology;ActiveingredientsoftraditionalChinesemedicine前言铜绿假单胞菌是一种广泛分布在环境中的革兰阴性菌,通常栖息在土壤,水,植物和人类中。它也是一种具有环境弹性的微生物,可以在营养缺乏的条件下生长,并在4至42°C的宽温度范围内生活。铜绿假单胞菌的顽强适应性和生存能力使其能够在医院干燥的非生物表面上存活长达6个月,可感染囊性纤维化、烧伤创面ADDINEN.CITE<EndNote><Cite><Author>Scheffler</Author><Year>2022</Year><RecNum>87</RecNum><DisplayText>[1]</DisplayText><record><rec-number>87</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685856661">87</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Scheffler,R.J.</author><author>Bratton,B.P.</author><author>Gitai,Z.</author></authors></contributors><auth-address>DepartmentofMolecularBiology,PrincetonUniversity,Princeton,NewJersey,UnitedStatesofAmerica. DepartmentofEmbryology,CarnegieInstitutionforScience,Baltimore,Maryland,UnitedStatesofAmerica. DepartmentofPathology,ImmunologyandMicrobiology,VanderbiltUniversityMedicalCenter,Nashville,Tennessee,UnitedStatesofAmerica. VanderbiltInstituteforInfection,Immunology,andInflammation,Nashville,Tennessee,UnitedStatesofAmerica.</auth-address><titles><title>Pseudomonasaeruginosaclinicalbloodisolatesdisplaysignificantphenotypicvariability</title><secondary-title>PLoSOne</secondary-title></titles><periodical><full-title>PLoSOne</full-title></periodical><pages>e0270576</pages><volume>17</volume><number>7</number><edition>2022/07/07</edition><keywords><keyword>BiologicalVariation,Population</keyword><keyword>Humans</keyword><keyword>*PseudomonasInfections</keyword><keyword>*Pseudomonasaeruginosa</keyword><keyword>Pyocyanine</keyword><keyword>VirulenceFactors/genetics</keyword></keywords><dates><year>2022</year></dates><isbn>1932-6203</isbn><accession-num>35793311</accession-num><urls></urls><custom2>PMC9258867</custom2><electronic-resource-num>10.1371/journal.pone.0270576</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[1]、免疫缺陷、慢性阻塞性肺疾病(COPD)、癌症和需要通气的严重感染(如COVID-19)患者。铜绿假单胞菌是一种机会性病原体,可引起烧烫伤病人、重症病人和免疫功能低下患者的院内感染。在环境中无处不在,特别是在医院中传播,由于对药物有着天生抗药性,以及部分对药物不恰当的使用导致其耐药性日渐增加,甚至有时候出现了多药耐药等情况,为临床使用抗生素治疗带来了极大挑战,成为对人类健康的主要威胁之一。由于铜绿假单胞菌的耐药现象越来越严重ADDINEN.CITEADDINEN.CITE.DATA[2],铜绿假单胞菌的耐药性现已成为临床上亟需解决的难题。近年来研究不断发现中草药对细菌的抑制作用ADDINEN.CITE<EndNote><Cite><Author>Hayashi</Author><Year>2021</Year><RecNum>89</RecNum><DisplayText>[3]</DisplayText><record><rec-number>89</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685856904">89</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Hayashi,M.</author><author>Kaneko,H.</author><author>Yamada,T.</author><author>Ikoshi,H.</author><author>Noguchi,N.</author><author>Nakaminami,H.</author></authors></contributors><auth-address>DepartmentofClinicalMicrobiology,SchoolofPharmacy,TokyoUniversityofPharmacyandLifeSciences,1432-1Horinouchi,Hachioji,Tokyo,Japan. DepartmentofTraditionalChineseMedicine,SchoolofPharmacy,TokyoUniversityofPharmacyandLifeSciences,1432-1Horinouchi,Hachioji,Tokyo,Japan.</auth-address><titles><title>ChineseherbalmedicinesandnutraceuticalsinhibitPseudomonasaeruginosabiofilmformation</title><secondary-title>AccessMicrobiol</secondary-title></titles><periodical><full-title>AccessMicrobiol</full-title></periodical><pages>000254</pages><volume>3</volume><number>8</number><edition>2021/12/11</edition><keywords><keyword>Chineseherbalmedicine</keyword><keyword>Pseudomonasaeruginosa</keyword><keyword>biofilm</keyword><keyword>nutraceutical</keyword></keywords><dates><year>2021</year></dates><isbn>2516-8290</isbn><accession-num>34888483</accession-num><urls></urls><custom2>PMC8650844</custom2><electronic-resource-num>10.1099/acmi.0.000254</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[3]。我国中草药资源丰富ADDINEN.CITE<EndNote><Cite><Author>Pang</Author><Year>2021</Year><RecNum>88</RecNum><DisplayText>[4]</DisplayText><record><rec-number>88</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685856852">88</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Pang,Z.</author><author>Zhu,Q.</author></authors></contributors><auth-address>InnovativeInstituteofChineseMedicineandPharmacy,ShandongUniversityofTraditionalChineseMedicine,Jinan,China. KeyLaboratoryofTraditionalChineseMedicineClassicalTheory,MinistryofEducation,ShandongUniversityofTraditionalChineseMedicine,Jinan,China. ShandongProvincialKeyLaboratoryofTraditionalChineseMedicineforBasicResearch,ShandongUniversityofTraditionalChineseMedicine,Jinan,China.</auth-address><titles><title>TraditionalChineseMedicineisanAlternativeTherapeuticOptionforTreatmentofPseudomonasaeruginosaInfections</title><secondary-title>FrontPharmacol</secondary-title></titles><periodical><full-title>FrontPharmacol</full-title></periodical><pages>737252</pages><volume>12</volume><edition>2021/09/14</edition><keywords><keyword>Pseudomonasaeruginosa</keyword><keyword>bactericidaleffects</keyword><keyword>biofilm</keyword><keyword>immunomodulation</keyword><keyword>quorumsensing</keyword><keyword>traditionalChinesemedicine</keyword><keyword>commercialorfinancialrelationshipsthatcouldbeconstruedasapotential</keyword><keyword>conflictofinterest.</keyword></keywords><dates><year>2021</year></dates><isbn>1663-9812(Print) 1663-9812</isbn><accession-num>34512364</accession-num><urls></urls><custom2>PMC8429605</custom2><electronic-resource-num>10.3389/fphar.2021.737252</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[4],使用历史悠久,具有相对可靠的使用安全性。由于清热解毒类中草药成分特殊、复杂,抗菌作用和机制原理不单一ADDINEN.CITE<EndNote><Cite><Author>Qin</Author><Year>2022</Year><RecNum>90</RecNum><DisplayText>[5]</DisplayText><record><rec-number>90</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685856991">90</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Qin,J.</author><author>Zou,C.</author><author>Tao,J.</author><author>Wei,T.</author><author>Yan,L.</author><author>Zhang,Y.</author><author>Wang,H.</author></authors></contributors><auth-address>DepartmentofClinicalLaboratory,YueyangHospitalofIntegratedTraditionalChineseandWesternMedicine,ShanghaiUniversityofTraditionalChineseMedicine,Shanghai,People'sRepublicofChina. DepartmentofMedicalTechnology,YueyangClinicalMedicalCollege,ShanghaiUniversityofTraditionalChineseMedicine,Shanghai,People'sRepublicofChina.</auth-address><titles><title>CarbapenemResistantPseudomonasaeruginosaInfectionsinElderlyPatients:AntimicrobialResistanceProfiles,RiskFactorsandImpactonClinicalOutcomes</title><secondary-title>InfectDrugResist</secondary-title></titles><periodical><full-title>InfectDrugResist</full-title></periodical><pages>2301-2314</pages><volume>15</volume><edition>2022/05/07</edition><keywords><keyword>Pseudomonasaeruginosa</keyword><keyword>carbapenem-resistant</keyword><keyword>infection</keyword><keyword>mortality</keyword><keyword>riskfactors</keyword><keyword>publicationofthisarticle.</keyword></keywords><dates><year>2022</year></dates><isbn>1178-6973(Print) 1178-6973</isbn><accession-num>35517901</accession-num><urls></urls><custom2>PMC9064054</custom2><electronic-resource-num>10.2147/idr.S358778</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[5],所以很少发现其耐药性,但存在抑菌作用有限、抑菌效果不稳定、抑菌机制不清楚等问题。中西药的使用各有优缺点,而中西药物合用则可以优势互补,所以中草药和抗生素的联合应用具有广阔的研究空间和开发前景。本项研究以中药活性成分和抗生素联用对铜绿假单胞菌耐药性的抑制效果作为研究对象,为铜绿假单胞菌ADDINEN.CITEADDINEN.CITE.DATA[6]的临床用药提供新的思路。一、实验材料(一)实验对象1.收集的34株临床分离铜绿假单胞菌来源于盱眙县人民医院医学检验科。5株分离自禽类标本,来源于扬州大学兽医学院人兽共患病实验室。2.铜绿假单胞菌ATCC27853是由扬州大学医学院病原生物室保存的抗菌药物敏感性试验质控菌株。(二)实验试剂试剂、耗材厂家氯化钠北京索莱宝科技有限公司胰蛋白胨OXOID琼脂GMATE酵母提取物OXOID琼脂糖Bioweste2×Taq

Plus

Master

Mix南京诺唯赞生物科技股份有限公司96孔聚苯乙烯板无锡耐思生命科技股份有限公司Gold

view核酸染料生物工程(上海)股份有限公司MH培养基杭州滨和微生物试剂有限公司DL2000

PIus

DNA

Marker南京诺唯赞生物科技股份有限公司抗生素:哌拉西林、替卡西林、头孢他啶、美罗培南、多粘菌素E、庆大霉素、妥布霉素、四环素、左氧氟沙星购买自大连美仑生物技术有限公司;环丙沙星购买自上海源叶生物科技有限公司。连翘脂苷-A、木犀草素、蜂毒素购自阿拉丁生化科技股份有限公司(三)实验仪器仪器厂家纯水仪ΜLUP-

Ⅲ-5T四川优普超纯科技有限公司立式高压蒸汽灭菌锅日本TOMY公司生物安全柜美国Thermo公司DNP-9162型恒温培养箱上海博迅医疗生物仪器股份有限公司恒温摇床德国Eppendorf公司PCR仪美国应用生物系统公司电泳仪美国Bio-RAD公司全自动凝胶成像仪英国SYNGENE公司细菌比浊仪英国OXOID公司微波炉格兰仕集团微量移液器赛默飞世尔科技公司冰箱(4℃和-20℃)海尔集团多功能酶标仪美国Biotek公司二、实验方法(一)药敏试验1.菌液制备:(1)菌种复苏:将冻存的铜绿假单胞菌菌种从-80℃低温冰箱中取出,待菌液解冻后无菌条件下接种环取菌液涂布LB固体培养基,于37℃培养箱中过夜培养。(2)挑取单个菌落接种于LB液体培养基,于37℃,200rmp恒温摇床过夜培养。(3)取20μL菌液,按照1:100的比例接种2mLMH肉汤培养基37℃,200rmp恒温摇床5-7小时,制备细菌悬液。(4)等上述菌悬液培养至OD600值为0.5麦氏比浊时,用MH培养基将其稀释1000倍备用(1×105CFU/mL)。2.抗生素及中药活性成分母液的配制:(1)连翘脂苷-A、木犀草素和蜂毒素配置成浓度分别为916μg/mL、800μg/mL、256μg/mL的母液备用。(2)根据CLSI《M100抗微生物药物敏感性试验执行标准》中选出10种药,其浓度分别为:哌拉西林4-256μg/mL、替卡西林4-256μg/mL、头孢他啶2-128μg/mL、氨曲南2-128μg/mL、美罗培南2-128μg/mL、多粘菌素E0.25-16μg/mL、庆大霉素2-128μg/mL、妥布霉素2-128μg/mL、环丙沙星0.5-32μg/mL、左氧氟沙星2-128μg/mL。(3)将哌拉西林、替卡西林、头孢他啶、氨曲南、美罗培南、多粘菌素E、庆大霉素、妥布霉素、环丙沙星、左氧氟沙星配置成浓度分别为1024μg/mL、1024μg/mL、512μg/mL、512μg/mL、512μg/mL、64μg/mL、512μg/mL、512μg/mL、128μg/mL、512μg/mL的母液备用。3.微量肉汤稀释法测抗生素和中药活性成分的MIC:(1)96孔板每孔均加100μLMH培养基(阴性对照加200μL)。(2)第一排各加100μL相应抗生素(哌拉西林、替卡西林、头孢他啶、氨曲南、美罗培南、多粘菌素E、庆大霉素、妥布霉素、环丙沙星、左氧氟沙星)及中药母液后,倍比稀释,每种抗生素及中药活性成分各设置3个复孔和阴性对照。(3)将用MH培养基稀释好的100μL的菌液(1×105CFU/mL),接种到上述96孔板中,接种完毕后用封口膜密封,于37℃培养箱培养18-20h后观察有无细菌生长并记录其结果。(4)判定标准:阳性对照组呈现浑浊或有菌沉淀状态,阴性对照组呈现透明澄清状态,根据CLSI《M100抗微生物药物敏感性试验执行标准》和每孔浑浊度读取各孔MIC值。(二)抗生素与中药活性成分联合抑菌实验1.按上述方法配制1×105CFU/mL菌液备用。2.取96孔聚苯乙烯板,纵向(A~H)按升浓度梯度加中药活性成分药液,每孔分别加入50μL,;横向(1~8)按降浓度梯度加抗生素溶液,每孔分别加入50μL,在加有药物的孔中再加入100μL备用的菌悬液;取4个空白孔加200μL

MH液体培养基作为阴性对照;取4个空白孔加入100μLMH液体培养基和100μL菌悬液作为阳性对照。将菌液混匀后封口膜封口,37℃培养箱孵育18-20h后用酶标仪测定菌液的吸光度(滤光片波长为595nm),计算平均光密度。抑制浓度(FIC)指数公式计算:FIC

=(A药物联合MIC/A药物单独MIC)+(B药物联合MIC/B药物单独MIC)。

判定标准如下:协同作用:FIC指数

0.5;部分协同作用:0.5

<

FIC指数

<

1;加性效应:FIC指数

=

1;无差别效果:

1

<

FIC指数

<

4;拮抗作用:FIC指数≥4。(三)生物膜抑制实验1.按上述方法配制1×105CFU/mL菌液备用2.取无菌96孔聚苯乙烯板,纵向(A-F),每行3个复孔,每孔加入100μL的LB液体培养基和100μL的菌悬液。阴性对照孔每孔加入200μLLB液体培养基,阳性对照孔加入100μLLB液体培养基和100μL菌悬液,阴阳对照组各3个复孔,封口后置于37℃培养箱培养24h。24h后,无菌吸弃孔内菌液,无菌PBS缓冲液轻柔洗孔2次,每行依次加入200μL配制好的6.25μg/mL、3.125μg/mL、1.57

μg/mL、0.78

μg/mL、0.39

μg/mL药液,阴阳对照加入200μL

LB液体培养基,封口后于37℃培养箱孵育24h。3.24h后,弃上清后用200μL的PBS轻柔清洗每孔两次,加入0.5%结晶紫染色避光37℃孵育30min,PBS冲洗2次后加入95%乙醇脱色后,酶标仪测定样品在595nm处的吸光度,计算平均光密度值。三、实验结果(一)菌株来源及分布共40株铜绿假单胞菌,其中质控菌株ATCC27853及39株来源于不同的科室及标本类型。标本类型分别是痰液分离株27株,脓液分离株2株,尿液分离株2株,血液分离株2株,分泌物分离株1株以及禽类5株。菌株样本科室以呼吸内科和神经外科为主。图140株铜绿假单胞菌来源及分布图240株铜绿假单胞菌科室来源及分布(二)ATCC27853及39株铜绿假单胞菌药敏结果共收集39株铜绿假单胞菌,按实验顺序将其命名为PA1-PA39。药敏实验共检测了8大类10抗生素,他们分别:哌拉西林(青霉素类)、替卡西林(β-内酰胺类)、头孢他啶(头孢类)、氨曲南(单环内酰胺类)、美罗培南(碳青霉烯类)、庆大霉素(氨基糖苷类)、妥布霉素(氨基糖苷类)、环丙沙星(喹诺酮类)、左氧氟沙星(喹诺酮类)。对青霉素类耐药的有PA17、PA18、PA22、PA23,占比10%;对β-内酰胺类耐药的有PA17、PA18、PA19、PA20、PA21、PA22、PA23,占比17.5%;对头孢类耐药的有PA17、PA18、PA19、PA20、PA21、PA22、PA23,占比17.5%;对单环内酰胺类耐药的有PA17、PA18、PA22、PA23、PA24,占比12.5%;青霉烯类耐药的有PA1、PA6、PA7、PA8、PA9、PA10、PA11、PA12、PA14、PA15、PA16、PA17、PA18、PA19、PA20、PA21、PA22、PA23、PA24、PA29,占比50%;对氨基糖苷类耐药的有PA3、PA17、PA18、PA22、PA23,庆大霉素占比12.5%,妥布霉素占比10%;对喹诺酮类耐药的有PA1、PA2、PA3、PA13、PA14、PA16、PA17、PA18、PA22、PA23,环丙沙星20%,左氧氟沙星25%。具体结果如表1、2,图3、4所示。表1ATCC27853及39株铜绿假单胞菌药敏结果抗生素ATCC27853PA1PA2PA3PA4哌拉西林<4(S)<4(S)<4(S)<4(S)<4(S)替卡西林<4(S)64(I)8(S)8(S)8(S)头孢他啶<1(S)<2(S)<2(S)<2(S)<2(S)氨曲南<1(S)8(S)<2(S)<2(S)<2(S)美罗培南<0.25(S)8(R)<2(S)<2(S)<2(S)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素<0.5(S)4(S)<2(S)16(R)<2(S)妥布霉素<0.5(S)<2(S)<2(S)8(I)<2(S)环丙沙星<0.125(S)32(R)4(R)16(R)<0.5(S)左氧氟沙星<0.25(S)128(R)16R8(R)<2(S)耐药:R,中介:I,敏感:S抗生素PA5PA6PA7PA8PA9哌拉西林<4(S)8(S)8(S)8(S)8(S)替卡西林<4(S)64(I)64(I)64(I)32(I)头孢他啶<2(S)<2(S)<2(S)<2(S)<2(S)氨曲南<2(S)16(I)8(S)16(I)8(S)美罗培南<2(S)32(R)16(R)32(R)32(R)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素8(I)<2(S)<2(S)<2(S)<2(S)妥布霉素4(S)<2(S)<2(S)<2(S)<2(S)环丙沙星<0.5(S)<0.5(S)<0.5(S)<0.5(S)<0.5(S)左氧氟沙星<2(S)<2(S)<2(S)<2(S)<2(S)耐药:R,中介:I,敏感:S抗生素PA10PA11PA12PA13PA14哌拉西林8(S)32(I)32(I)<4(S)16(S)替卡西林64(I)64(I)32(I)8(S)64(I)头孢他啶<2(S)4(S)4(S)<2(S)4(S)氨曲南8(S)16(I)4(S)<2(S)8(S)美罗培南32(R)32(R)8(R)4(I)32(R)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素<2(S)<2(S)<2(S)<2(S)<2(S)妥布霉素<2(S)<2(S)<2(S)<2(S)<2(S)环丙沙星<0.5(S)<0.5(S)<0.5(S)<0.5(S)4(R)左氧氟沙星<2(S)<2(S)<2(S)4(R)16(R)耐药:R,中介:I,敏感:S抗生素PA15PA16PA17PA18PA19哌拉西林8(S)8(S)>256(R)128(R)8(S)替卡西林64(I)64(I)>256(R)>256(R)256(R)头孢他啶<2(S)<2(S)128(R)>128(R)>128(R)氨曲南8(S)8(S)128(R)>128(R)<2(S)美罗培南16(R)32(R)32(R)32(R)64(R)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素<2(S)<2(S)>128(R)>128(R)4(S)妥布霉素<2(S)<2(S)>128(R)>128(R)4(S)环丙沙星<0.5(S)1(I)32(R)32(R)<0.5(S)左氧氟沙星<2(S)8(R)32(R)32(R)<2(S)耐药:R,中介:I,敏感:S抗生素PA20PA21PA22PA23PA24哌拉西林<4(S)8(S)>256(R)128(R)8(S)替卡西林>256(R)>256(R)>256(R)>256(R)64(I)头孢他啶>128(R)>128(R)>128(R)64(R)4(S)氨曲南4(S)4(S)>128(R)64(R)32(R)美罗培南64(R)128(R)8(R)8(R)32(R)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素4(S)4(S)>128(R)>128(R)<2(S)妥布霉素<2(S)<2(S)>128(R)>128(R)<2(S)环丙沙星<0.5(S)<0.5(S)8(R)4(R)<0.5(S)左氧氟沙星<2(S)<2(S)8(R)8(R)<2(S)耐药:R,中介:I,敏感:S抗生素PA25PA26PA27PA28PA29哌拉西林<4(S)<4(S)<4(S)<4(S)<4(S)替卡西林8(S)16(S)8(S)16(S)32(I)头孢他啶<2(S)<2(S)<2(S)<2(S)<2(S)氨曲南4(S)5(S)2(S)<2(S)4(S)美罗培南<2(S)<2(S)<2(S)<2(S)16(R)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素<2(S)<2(S)<2(S)<2(S)<2(S)妥布霉素<2(S)<2(S)<2(S)<2(S)<2(S)环丙沙星<0.5(S)<0.5(S)<0.5(S)<0.5(S)<0.5(S)左氧氟沙星<2(S)<2(S)<2(S)<2(S)<2(S)耐药:R,中介:I,敏感:S抗生素PA30PA31PA32PA33PA34哌拉西林<4(S)<4(S)<4(S)<4(S)<4(S)替卡西林8(S)8(S)16(S)<4(S)<4(S)头孢他啶<2(S)<2(S)<2(S)<2(S)<2(S)氨曲南4(S)<2(S)<2(S)<2(S)<2(S)美罗培南<2(S)<2(S)<2(S)<2(S)<2(S)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素<2(S)<2(S)<2(S)<2(S)<2(S)妥布霉素<2(S)<2(S)<2(S)<2(S)<2(S)环丙沙星<0.5(S)<0.5(S)<0.5(S)<0.5(S)<0.5(S)左氧氟沙星<2(S)<2(S)<2(S)<2(S)<2(S)耐药:R,中介:I,敏感:S抗生素PA35PA36PA37PA38PA39哌拉西林<4(S)<4(S)<4(S)<4(S)<4(S)替卡西林<4(S)<4(S)<4(S)16(S)8(S)头孢他啶<2(S)<2(S)<2(S)<2(S)<2(S)氨曲南<2(S)<2(S)<2(S)<2(S)<2(S)美罗培南<2(S)<2(S)<2(S)<2(S)<2(S)多粘菌素E<0.25(S)<0.25(S)<0.25(S)<0.25(S)<0.25(S)庆大霉素<2(S)<2(S)<2(S)<2(S)<2(S)妥布霉素<2(S)<2(S)<2(S)<2(S)<2(S)环丙沙星<0.5(S)<0.5(S)<0.5(S)<0.5(S)<0.5(S)左氧氟沙星<2(S)<2(S)<2(S)<2(S)<2(S)耐药:R,中介:I,敏感:S表2ATCC27853及39株铜绿假单胞菌药敏结果汇总表抗生素分类抗生素名称数量(%)耐药中介敏感青霉素类哌拉西林4(10)2(5)34(85)β-内酰胺类替卡西林7(17.5)13(32.5)20(50)头孢类头孢他啶7(17.5)0(0)33(82.5)单环内酰胺类氨曲南5(12.5)3(7.5)32(80)碳青霉烯类美罗培南20(50)1(2.5)19(47.5)脂肽类多粘菌素E0(0)0(0)40(100)氨基糖苷类庆大霉素5(12.5)1(2.5)34(85)妥布霉素4(10)1(2.5)35(87.5)氟喹诺酮类环丙沙星8(20)1(2.5)31(77.5)左氧氟沙星10(25)0(0)30(75)图3ATCC27853及39株铜绿假单胞菌药敏统计图4ATCC27853及39株铜绿假单胞菌药敏统计(三)耐药性情况分析当菌株对一种药物耐药的同时,对其他两种结构和机制不同的药物也产生耐药性时,称之为多重耐药菌。对除多黏菌素、替加环素外都耐药的菌株则称为泛耐药菌。对所有抗生素都敏感的则称之为敏感菌。39株临床分离铜绿假单胞菌中多重耐药菌7株,占比17.9%;泛耐药菌4株,占比10.3%;敏感菌16株,占比41%。如图5所示。图5ATCC27853及39株分离铜绿假单胞菌耐药性统计(四)中药活性成分单独抑菌结果中药活性成分对标准菌株和多重耐药菌株PA9、PA14、PA35、PA36进行单独抑菌实验,木犀草素的MIC均大于229,连翘酯苷A的MIC均大于200,蜂毒素只有PA14的MIC为16,其他均为8,如表3所示。表3中药活性成分抑制铜绿假单胞菌药敏结果中药(μg/mL)ATCC27853PA9PA14PA35PA36木犀草素>229>229>229>229>229连翘酯苷A>200>200>200>200>200蜂毒素881688(五)中药活性成分联合常见抗生素抑制铜绿假单胞菌选择泛耐药菌PA17、PA18,多重耐药菌PA37作为研究对象,进行联合抑菌实验。美罗培南与连翘酯苷A、左氧氟沙星与蜂毒素联用对PA17的抑制效果的效果均不佳,庆大霉素、环丙沙星和头孢他啶与蜂毒素联用对PA18的抑制效果均不佳,环丙沙星和庆大霉素与蜂毒素联用对PA37的抑制效果均不佳,结果如图6所示。图6(六)蜂毒素对铜绿假单胞菌生物膜抑制结果选择泛耐药菌株PA12、PA17、PA18以及多重耐药菌株PA9、PA35作为研究对象进行生物膜抑制实验,蜂毒素仅对PA9的生物膜表现出显著抑制性,对PA12、PA17、PA18和PA35的生物膜均无明显抑制性,结果如图7所示。图7四、讨论39株临床分离的铜绿假单胞菌主要来源于呼吸内科,说明呼吸道感染ADDINEN.CITE<EndNote><Cite><Author>Jurado-Martín</Author><Year>2021</Year><RecNum>95</RecNum><DisplayText>[7]</DisplayText><record><rec-number>95</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685964354">95</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Jurado-Martín,I.</author><author>Sainz-Mejías,M.</author><author>McClean,S.</author></authors></contributors><auth-address>SchoolofBiomolecularandBiomedicalSciences,UniversityCollegeDublin,Belfield,Dublin4D04V1W8,Ireland.</auth-address><titles><title>Pseudomonasaeruginosa:AnAudaciousPathogenwithanAdaptableArsenalofVirulenceFactors</title><secondary-title>IntJMolSci</secondary-title></titles><periodical><full-title>IntJMolSci</full-title></periodical><volume>22</volume><number>6</number><edition>2021/04/04</edition><keywords><keyword>*Adaptation,Physiological</keyword><keyword>Animals</keyword><keyword>Biofilms/growth&development</keyword><keyword>Humans</keyword><keyword>Lung/microbiology</keyword><keyword>Pseudomonasaeruginosa/genetics/*pathogenicity/*physiology</keyword><keyword>QuorumSensing</keyword><keyword>VirulenceFactors/*metabolism</keyword><keyword>Pseudomonasaeruginosa</keyword><keyword>adaptation</keyword><keyword>cysticfibrosis</keyword><keyword>diversity</keyword><keyword>genomics</keyword><keyword>lungenvironment</keyword><keyword>virulencefactors</keyword><keyword>writingofthemanuscript,orinthecontentofthereview.</keyword></keywords><dates><year>2021</year><pub-dates><date>Mar18</date></pub-dates></dates><isbn>1422-0067</isbn><accession-num>33803907</accession-num><urls></urls><custom2>PMC8003266</custom2><electronic-resource-num>10.3390/ijms22063128</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[7]是铜绿假单胞菌传播的主要途径之一。铜绿假单胞菌是一种机会性病原体,可引起烧烫伤病人ADDINEN.CITEADDINEN.CITE.DATA[8]、重症病人和免疫功能低下患者的院内感染。在环境中无处不在,特别是在医院中传播ADDINEN.CITE<EndNote><Cite><Author>张娟</Author><Year>2022</Year><RecNum>79</RecNum><DisplayText>[9]</DisplayText><record><rec-number>79</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685804901">79</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>张娟</author><author>綦艳</author><author>周臣清</author><author>赵玲</author><author>黄宝莹</author><author>杨纯佳</author><author>佘之蕴</author></authors></contributors><auth-address>广东产品质量监督检验研究院;广东省食品生物危害因素监测工程技术研究中心;</auth-address><titles><title>61株水源性铜绿假单胞菌耐药分析及其16SrRNA系统发育学研究</title><secondary-title>食品安全质量检测学报</secondary-title></titles><periodical><full-title>食品安全质量检测学报</full-title></periodical><pages>4150-4156</pages><volume>13</volume><number>13</number><keywords><keyword>铜绿假单胞菌</keyword><keyword>16SrRNA</keyword><keyword>系统发生树</keyword><keyword>抗生素耐药</keyword></keywords><dates><year>2022</year></dates><isbn>2095-0381</isbn><call-num>11-5956/TS</call-num><urls></urls><electronic-resource-num>10.19812/ki.jfsq11-5956/ts.2022.13.056</electronic-resource-num><remote-database-provider>Cnki</remote-database-provider></record></Cite></EndNote>[9]。铜绿假单胞菌的耐药性主要集中在β-内酰胺类和碳青霉烯ADDINEN.CITEADDINEN.CITE.DATA[10]类,铜绿假单胞菌产生β-内酰胺酶,能够降解抗生素,对药物有着天生抗药性。部分对药物不恰当的使用导致铜绿假单胞菌耐药性日渐增加,甚至有时候出现了多药耐药等情况,为临床使用抗生素治疗ADDINEN.CITE<EndNote><Cite><Author>Lila</Author><Year>2018</Year><RecNum>80</RecNum><DisplayText>[11]</DisplayText><record><rec-number>80</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685804958">80</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Lila,G.</author><author>Mulliqi,G.</author><author>Raka,L.</author><author>Kurti,A.</author><author>Bajrami,R.</author><author>Azizi,E.</author></authors></contributors><auth-address>DepartmentofMicrobiology,FacultyofMedicineUniversityofPristina,Pristina,Kosovo,lul.raka@. DepartmentofMicrobiology,NationalInstituteofPublicHealthofKosovo,Pristina,Kosovo,lul.raka@. FoodscienceandTechnology,FacultyofAgricultureandVeterinary,UniversityofPristina,Pristina,Kosovo.</auth-address><titles><title>MolecularepidemiologyofPseudomonasaeruginosainUniversityClinicalCenterofKosovo</title><secondary-title>InfectDrugResist</secondary-title></titles><periodical><full-title>InfectDrugResist</full-title></periodical><pages>2039-2046</pages><volume>11</volume><edition>2018/11/23</edition><keywords><keyword>Icu</keyword><keyword>P.aeruginosa</keyword><keyword>genotyping</keyword><keyword>nosocomialinfection</keyword><keyword>pulsed-fieldgelelectrophoresis</keyword></keywords><dates><year>2018</year></dates><isbn>1178-6973(Print) 1178-6973</isbn><accession-num>30464546</accession-num><urls></urls><custom2>PMC6208869</custom2><electronic-resource-num>10.2147/idr.S174940</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[11]带来了极大挑战,成为对人类健康的主要威胁之一。多重耐药和泛耐药ADDINEN.CITEADDINEN.CITE.DATA[12]铜绿假单胞菌菌株的出现和传播已经成为公共卫生主要关注的问题之一。多重耐药性的主要后果之一是难以选择适当的经验性抗生素治疗。多重耐药性或泛耐药性病原体感染的患者在接受不足的初始抗菌治疗后风险增加,延迟接受有效抗生素治疗使铜绿假单胞菌血流感染患者的结局更差和死亡率较高。铜绿假单胞菌引起严重感染ADDINEN.CITE<EndNote><Cite><Author>Hafiz</Author><Year>2023</Year><RecNum>69</RecNum><DisplayText>[13]</DisplayText><record><rec-number>69</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685798823">69</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Hafiz,T.A.</author><author>BinEssa,E.A.</author><author>Alharbi,S.R.</author><author>Alyami,A.S.</author><author>Alkudmani,Z.S.</author><author>Mubaraki,M.A.</author><author>Alturki,N.A.</author><author>Alotaibi,F.</author></authors></contributors><auth-address>ClinicalLaboratorySciencesDepartment,CollegeofAppliedMedicalSciences,KingSaudUniversity,Riyadh12372,SaudiArabia. PathologyandClinicalLaboratoryMedicine,KingFahadMedicalCity,Riyadh11525,SaudiArabia. PathologyDepartment,CollegeofMedicine,KingSaudUniversity,Riyadh12372,SaudiArabia.</auth-address><titles><title>Epidemiological,Microbiological,andClinicalCharacteristicsofMulti-ResistantPseudomonasaeruginosaIsolatesinKingFahadMedicalCity,Riyadh,SaudiArabia</title><secondary-title>TropMedInfectDis</secondary-title></titles><periodical><full-title>TropMedInfectDis</full-title></periodical><volume>8</volume><number>4</number><edition>2023/04/27</edition><keywords><keyword>Covid-19</keyword><keyword>Pseudomonasaeruginosa</keyword><keyword>intensivecareunit</keyword><keyword>multi-drugresistant</keyword><keyword>nosocomialinfection</keyword><keyword>pan-drugresistant</keyword><keyword>respiratory</keyword></keywords><dates><year>2023</year><pub-dates><date>Mar30</date></pub-dates></dates><isbn>2414-6366</isbn><accession-num>37104331</accession-num><urls></urls><custom2>PMC10145365</custom2><electronic-resource-num>10.3390/tropicalmed8040205</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[13],特别是在住院患者和免疫功能低下患者中。铜绿假单胞菌是一种革兰阴性条件致病菌,是引发院内感染的病原体之一,常因呼吸道感染ADDINEN.CITEADDINEN.CITE.DATA[14]、血流感染、皮肤感染、中枢神经系统感染等ADDINEN.CITE<EndNote><Cite><Author>Glen</Author><Year>2021</Year><RecNum>57</RecNum><DisplayText>[15]</DisplayText><record><rec-number>57</rec-number><foreign-keys><keyapp="EN"db-id="azzesezab0zxw4e20z4pdwexp5ppdvzz0rw9"timestamp="1685771286">57</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Glen,K.A.</author><author>Lamont,I.L.</author></authors></contributors><auth-address>DepartmentofBiochemistry,UniversityofOtago,P.O.Box56,Dunedin9054,NewZealand.</auth-address><titles><title>β-lactamResistanceinPseudomonasaeruginosa:CurrentStatus,FutureProspects</title><secondary-title>Pathogens</secondary-title></titles><periodical><full-title>Pathogens</full-title></periodical><volume>10</volume><number>12</number><edition>2021/12/29</edition><keywords><keyword>AmpC</keyword><keyword>Pbp3</keyword><keyword>antibioticefflux</keyword><keyword>antibioticresistance</keyword><keyword>carbapenem</keyword><keyword>carbapenemase</keyword><keyword>cephalosporin</keyword><keyword>cysticfibrosis</keyword><keyword>nosocomialinfection</keyword><keyword>β-lactamase</keyword></keywords><dates><year>2021</year><pub-dates><date>Dec18</date></pub-dates></dates><isbn>2076-0817(Print) 2076-0817</isbn><accession-num>34959593</accession-num><urls></urls><custom2>PMC8706265</custom2><electronic-resource-num>10.3390/pathogens10121638</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[15]引起心内膜炎、脓胸、外耳道炎等疾病。其易感人群为免疫力低下或患有基础疾病的人群,与重症监护病房(ICU)内患者的患病率及死亡率相关。国内滥用抗生素现象严重ADDINEN.CITEADDINEN.CITE.DATA[16],耐药性流行率高于欧洲国家。自2011年起,我国加强了对抗生素使用的管理。抗生素的使用终究会对人体产生一系列副作用,而我国拥有丰富的中草药资源,于是尝试用中药活性成分抑制铜绿假单胞菌。然而单独使用中药活性成分抑制铜绿假单胞菌的效果不佳,于是考虑中药活性成分与抗生素联合使用。由于木犀草素和连翘酯苷A没有明显抑菌活性,而蜂毒素有一定抑菌活性,于是选择蜂毒素对泛耐

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论